Wei Ritzbi

Weilizhibo-B（09887）从2025年7月17日至2025年7月22日发表了一份股票。预计该公司将在全球范围内发行32,0544万股股票，其中香港要约的10％和90％的国际报价。提供的每项动作是每100股100股，31.6 hk $ 35.0 HK。预计将于2025年7月25日星期五开始在证券交易所报价。 该公司成立于2012年，是一家临床体育场生物技术公司，致力于发现，开发和销售针对肿瘤，自身免疫性疾病和其他重要疾病的新治疗方法。该公司具有一种核心产品，LBL-024（在注册的临床阶段，PD-L1和4-1BB的双极抗体），目前正在评估治疗对先进的肺癌前神经内管癌治疗的治疗的潜在疗效n-Small Cell Lung Cancer (As First Line Treatment), and Other Solid Tumors (As First Line Treatment) (AS First line treatment) (as First line treat) (As Third Line Therapy) (As Second Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Line Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy).Rapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third线疗法（作为第三线治疗）（作为第三线治疗）（作为第三线治疗）（作为第三线治疗）（作为第三线治疗）（作为第三线治疗）。第三李ne Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Line Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As ThirdLine Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) ( Third Line Therapy) (As Third Line Therapy) (As Third Line Therapy) （作为第三线治疗）（作为第三线治疗）作为排水疗法（作为第三行治疗）（作为第三行治疗）（作为第三行治疗）（作为第三行治疗）（作为第三线李ne Treatment) (as third line treatment) (as third line treatment) (as third line treatment) (as third line treatment) (as third line treatment) (as treatment of the third line) (as third -line treatment) (as third line treatment) (as third -line treatment) (as third -line treatment) (as third -line treatment) (as third -line treatment) (as third -line treatment) (as third -line treatment) Third Line therapy) (as third line therapy) (such as T therapyErcera Line) （作为第三线治疗）（作为第三线治疗）（作为第三线治疗）（作为第三线治疗）（第三行治疗）（ 该公司已与Cornerstone Investors，Gaoyi实体，Trumed，Orbimed，Huang River Investment Limited和Fund，Poresight Funds，Sage Partners和Hankang Entity签署了一项基石投资协议。 Cornerstone投资者同意订阅或鼓励指定实体，并订阅可以以要约价格购买的相关行动。 官方NINA Finance帐户 24-小时分发最新信息和财务视频的间隙传输，以及扫描QR码以跟随更多粉丝（Sinafinance）